An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer

BackgroundThere are no randomized control trials comparing the efficacy of trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer (mCRC). Herein, we conducted an observational study to compare the oncologic outcomes of trifluridine/tipiracil-containing regimen (TAS-102)...

Full description

Bibliographic Details
Main Authors: Meng-Che Hsieh, Kun-Ming Rau, Shung-Eing Lin, Kuang-Wen Liu, Chong-Chi Chiu, Chih-I Chen, Ling-Chiao Song, Hsin-Pao Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
metastatic colorectal carcinoma
trifluridine/tipiracil
regorafenib
oncologic outcome
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.867546/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.867546/full

Similar Items